Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

摘要：

Dear Editor,Monoclonal antibodies (mAbs) blocking immune checkpoint molecules,especially programmed cell death 1 (PD-1) and its ligands programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2),are currently been investigated for treatment of various tumors ”1-3”.

所属期刊栏目：27

资助基金：This work was supported by the Ministry of Science and Technology of China 973 program:2013CB531502 and 2014CB542503,the National Natural Science Foundation of China NSFC;31390432 and 31500722,Grand S&T project of China Health and Family Planning Commission 2013ZX10004608-002 and 2016ZX10004201-009,the Strategic Priority Research Program of the Chinese Academy of Sciences CAS;XDB08020100.We thank the staff of BL17U beamline at Shanghai Synchrotron Radiation Facility for assistance with data collection.YS is supported by the Excellent Young Scientist Program of CAS and the Youth Innovation Promotion Association of CAS 2015078.GFG is supported partly as a leading principal investigator of the NSFC Innovative Research Group 81321063.

在线出版日期：2017-02-27（万方平台首次上网日期，不代表论文的发表时间）

页码：151-153